Can flickering lights and sound leisurely the progression of Alzheimer’s disease? This innovative question is being explored by Annabelle Singer, an associate professor and biomedical engineer at the Georgia Institute of Technology and Emory University. Her research focuses on understanding neural activity patterns in the brain and identifying what goes wrong in Alzheimer’s patients, with the ultimate goal of developing new therapies.
“We are taking a really different approach to Alzheimer’s,” Singer explains. “We’ve determined how neural activity that is essential for memory fails in Alzheimer’s disease. We’re then using that information to develop brain stimulation that could improve brain health.” While significant funding is directed towards pharmaceutical research aimed at drug therapies, Singer’s method employs a unique non-invasive approach utilizing ski-goggle-like devices that deliver flickering lights and sound.
The goggles emit flickering lights at a rate approximately five times faster than typical strobe lights, while headphones produce rapid clicking and beeping sounds. This sensory stimulation aims to decode memory functions in Alzheimer’s patients and investigate how failures in neural activity contribute to memory impairments.
Promising Preliminary Findings
Initial preclinical studies and a feasibility study have indicated that this method could slow cognitive decline and volume loss in critical brain areas associated with memory. Specifically, exposure to flickering lights and sounds at a frequency of 40 Hz for an hour each day has shown potential benefits. “Both those things are really promising,” Singer notes. “We don’t know that we can reverse the memory impairment that’s already there. Instead, what we’re going for is to slow the continuing decline.”
According to Singer, traditional medications used to treat Alzheimer’s often come with serious side effects and limited efficacy. “The majority of research on Alzheimer’s disease focuses on the molecular scale — how proteins accumulate or go wrong,” she adds. “We’re asking, how do neurons behave electrically to generate memory and how do those patterns change in Alzheimer’s patients?”
Ongoing Clinical Trials
A Phase 3 double-blind clinical trial is currently underway, involving nearly 700 patients across 70 locations in the United States. This trial is being conducted by Cognito Therapeutics, a medtech company known for its innovative wearable devices. Although Singer is not directly leading the studies, she serves as a scientific adviser on Cognito’s board.
“The hope,” she states, “is that we will see people who are undergoing this stimulation have slower or no decline in cognitive function than people who are not getting treated.” This clinical trial is expected to wrap up later this year, and its findings could have significant implications for Alzheimer’s treatment options.
The Growing Need for Effective Treatments
Alzheimer’s disease currently affects more than 7 million Americans aged 65 or older, a number projected to rise to 13.8 million by 2060 if no significant medical breakthroughs occur. Globally, around 57 million people are living with dementia, with Alzheimer’s being the most prevalent form, as reported by the World Health Organization.
This alarming trend is driving increased research efforts, especially as the population ages. Recently, the U.S. Food and Drug Administration fast-tracked the approval of new medications like lecanemab and donanemab. However, there is some skepticism among healthcare professionals regarding whether the modest improvements noted in clinical trials justify the associated risks, which can include severe side effects such as brain swelling or bleeding.
Initial Success and Future Aspirations
James Lah, director of the Cognitive Neurology Program at Emory University and an associate professor of neurology, collaborated with Singer on an earlier proof-of-concept study examining 10 patients with mild cognitive impairment. These participants underwent treatments involving flickering lights and sounds for an hour a day over eight weeks. “This was the first human trial of this technology in this approach,” Lah remarked.
The findings from this initial study suggested beneficial effects, as notable changes were observed in both the patients’ spinal fluid and their electroencephalograms (EEGs), which measure brain wave activity. Lah noted, “We saw some really interesting changes in the patterns of electrical connectivity in patients after being exposed to this flicker.”
As her research continues, Singer remains hopeful about the accessibility of this intervention. “If we have a exceptionally safe, low-risk intervention, then I think that changes the equation,” she asserts. There is excitement around the potential of these goggles, as they could represent a significant advancement in the treatment of Alzheimer’s disease.
As the clinical trial progresses, the medical community watches closely for results that could reshape the landscape of Alzheimer’s treatment. The innovative approach of using external stimulation to modify brain activity is garnering interest and could lead to new avenues for patient care. “The whole notion of using external stimulation to modify brain activity is fascinating,” Lah said. “It’s just cool. I signify, certain things are just cool.”
This ongoing research underscores the urgent need for effective therapies in the face of a growing Alzheimer’s epidemic. As findings emerge, they may provide fresh hope for millions affected by this challenging disease.
For more insights into this groundbreaking research, feel free to share your thoughts and engage with us in the comments below.
Disclaimer: This article is for informational purposes only and is not intended as medical advice.
